Companies › QED Therapeutics, a BridgeBio company
1 active drug program in 1 registered trial: 1 Phase 2; Other; next expected readout Mar 2030.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Infigratinib Fibroblast growth factor receptor inhibitor | FGFR3, FGFR1, FGFR4, FGFR2 | Phase 2 | Achondroplasia | Mar 2030 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07169279 | Infigratinib | Phase 2 | Achondroplasia | Other | Mar 2030 |
Cash and short-term investments of $1.5bn on 2026-09-30; operating cash outflow about $419m a year; runway about 44 months at that burn, to May 2030; 1 of 1 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Tyra Biosciences Johnson & Johnson (Janssen) AstraZeneca Taiho Oncology Exelixis TransThera Sciences (Nanjing) Hutchmed Eisai Cogent Biosciences Xynomic Pharmaceuticals
Eloxx Pharmaceuticals Angitia Zynerba Pharmaceuticals Nocion Therapeutics Angitia Biopharmaceuticals Guangzhou
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.